



Personal information

First name/Surname *Rocco Cerroni*
work address Neurological Clinic, Department of System Medicine, University of Rome "Tor Vergata", Viale Oxford, 81, 00133 – Rome, Italy
mobile +39 3920634108
e-mail rocco.cerroni@gmail.com
nationality/residence Italian / Rome
date of birth 22/05/1985
gender Male

Education and Training

04/2023 Ph.D in Neuroscience (cum laude), University of Rome Tor Vergata, Italy
2019 Specialization in Neurology (50/50 cum laude) University of Rome Tor Vergata
Since 02/2015-ongoing Clinical research activities at Movement Disorders Centre, University of Rome Tor Vergata
Since 02/2015-ongoing Research activities in Experimental Neurology Laboratory, Neuroscience Department, University of Rome "Tor Vergata"
2014 License to Medical Practice (270/270), University of Rome "UCSC"
2013 Degree in Medicine and Surgery (110/110 cum laude), University of Rome "Cattolica del Sacro Cuore (UCSC)", Italy
10/2010 – 09/2013 Clinical research activities at Alzheimer Centre, University of Rome "Cattolica del Sacro Cuore", Italy
10/2010 – 09/2013 Neuropsychological formation at Alzheimer Centre, University of Rome "UCSC", Italy

Working activities

Since 12/2019-04/2023 **Neurologist – PhD bursary**
Movement Disorders Center, Policlinico Tor Vergata, Rome - Italy
Outpatients and Day Hospital service; sub-investigator in clinical trials; clinical and translational studies on Movement Disorders and other Neurodegenerative Diseases
Since 08/2022-ongoing **Neurologist – Dirigente Medico**
UOC Neurologia, Policlinico Tor Vergata, Rome – Italy.
Conductor of outpatient clinic for advanced-therapies in Parkinson's Disease; Outpatients, Day Hospital and Hospitalization service; Neurological Guard shifts.
02/2019-08/2021 **Neurologist**
Consultant at Policlinico Casilino, Rome

Skills

<i>Clinical skills</i>	High experience in: 1. Management of Movement Disorders, in particular advanced therapies for Parkinson's Disease (Deep Brain Stimulation, Levodopa Carbidopa Intestinal Gel, Subcutaneous Apomorphine Infusion, Magnetic Resonance guided Focused Ultrasound) 2. Neuropsychological tests for diagnosis of cognitive deficits
<i>Languages</i>	Excellent knowledge of English
<i>Computer/Statistics</i>	Microsoft Office, iOS, IBM – SPSS

Teaching activities

Since 12/2019-ongoing	Facoltà di Medicina e Chirurgia – University of Roma Tor Vergata, Italy <ul style="list-style-type: none">• <u>Adjunct Professor of Neurology for Bachelor of Science in Psychology</u>• <u>Neurology lectures for Degree Courses for Health Professions</u><ul style="list-style-type: none">- Physical Therapist Master- Biotechnology- Dentistry• <u>Role of “Cultore della materia” in Neurology</u><ul style="list-style-type: none">- Member of the examination board in neurology for the Degree Course of Medicine and Surgery• <u>Tutor</u> and theoretical-practical courses for students of Medicine, health professions and Neurology specialists• <u>Co-supervisor</u> in the degree thesis for Health Professions and Medicine and Surgery
Since 12/2019-ongoing	Movement Disorders Lectures and Webinars for Continuous Education in Medicine (ECM) Courses and Trainings promoted by Providers/Pharmaceutical Companies

Scientific publications

SCOPUS , *h-index* = 11

Peer-reviewed articles

- 1- Suppa A, Asci F, Costantini G, Bove F, Piano C, Pistoia F, **Cerroni R**, Brusa L, Cesarini V, Pietracupa S, Modugno N, Zampogna A, Sucapane P, Pierantozzi M, Tufo T, Pisani A, Peppe A, Stefani A, Calabresi P, Bentivoglio AR, Saggio G; Lazio DBS Study Group. Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis. *Front Neurol.* 2023 Oct 19;14:1267360. doi: 10.3389/fneur.2023.1267360. PMID: 37928137; PMCID: PMC10622670.
- 2- Conti M, Guerra A, Pierantozzi M, Bovenzi R, D'Onofrio V, Simonetta C, **Cerroni R**, Liguori C, Placidi F, Mercuri NB, Di Giuliano F, Schirinzi T, Stefani A. Band-Specific Altered Cortical

- Connectivity in Early Parkinson's Disease and its Clinical Correlates. *Mov Disord*. 2023 Oct 20. doi: 10.1002/mds.29615. Epub ahead of print. PMID: 37860930.
- 3- Moleti A, Minniti T, Viziano A, Stefani A, **Cerroni R**, Garasto E, Pierantozzi M, Sisto R. Enhanced suppression of otoacoustic emissions by contralateral stimulation in Parkinson's disease. *JASA Express Lett*. 2023 Oct 1;3(10):104401. doi: 10.1121/10.0021187. PMID: 37787697.
 - 4- Bovenzi R, Conti M, Degoli GR, **Cerroni R**, Artusi CA, Pierantozzi M, Stefani A, Mercuri NB, Schirinzi T. Pregnancy, fertile life factors, and associated clinical course in PRKN early-onset Parkinson's disease. *Neurol Sci*. 2023 Sep 2. doi: 10.1007/s10072-023-07029-8. PMID: 37658959.
 - 5- Schirinzi T, Maftai D, Grillo P, Bovenzi R, Bissacco J, Simonetta C, Mascioli D, Zenuni H, **Cerroni R**, Vincenzi M, Maurizi R, Passali FM, Di Girolamo S, Ralli M, Magliulo G, Tirassa P, Stefani A, Mercuri NB, Lattanzi R, Severini C. Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction. *Mov Disord*. 2023 May 8. doi: 10.1002/mds.29433. PMID: 37157902.
 - 6- Bovenzi R, Conti M, Degoli GR, **Cerroni R**, Simonetta C, Liguori C, Salimei C, Pisani A, Pierantozzi M, Stefani A, Mercuri NB, Schirinzi T. Shaping the course of early-onset Parkinson's disease: insights from a longitudinal cohort. *Neurol Sci*. 2023 May 4. doi: 10.1007/s10072-023-06826-5. PMID: 37140831.
 - 7- Garasto E, Stefani A, Pierantozzi M, **Cerroni R**, Conti M, Maranesi S, Mercuri NB, Chiaravallotti A, Schillaci O, Viziano A, Moleti A, Sisto R. Association between hearing sensitivity and dopamine transporter availability in Parkinson's disease. *Brain Commun*. 2023 Mar 21;5(2):fcad075. doi: 10.1093/braincomms/fcad075. PMID: 37006327.
 - 8- Bovenzi R, Sancesario GM, Conti M, Grillo P, **Cerroni R**, Bissacco J, Forti P, Giannella E, Pieri M, Minosse S, Ferrazzoli V, Pucci N, Laudazi M, Floris R, Garaci F, Pierantozzi M, Stefani A, Mercuri NB, Picchi E, Di Giuliano F, Schirinzi T. Sex hormones differentially contribute to Parkinson disease in males: A multimodal biomarker study. *Eur J Neurol*. 2023 Mar 27. doi: 10.1111/ene.15801. PMID: 36971787.
 - 9- Carpi M, Pierantozzi M, Cofano S, Fernandes M, **Cerroni R**, De Cillis F, Mercuri NB, Stefani A, Liguori C. "Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson's Disease: An Exploratory Study". *J Pers Med*. 2023 Jan 29;13(2):242. doi: 10.3390/jpm13020242. PMID: 36836476.
 - 10- Di Biase L, Piano C, Bove F, Ricci L, Caminiti ML, Stefani A, Viselli F, Modugno N, **Cerroni R**, Calabresi P, Bentivoglio AR, Tufo T, Di Lazzaro V; Lazio DBS Study Group. "Intraoperative Local Field Potential Beta Power and Three-Dimensional Neuroimaging Mapping Predict Long-Term Clinical Response to Deep Brain Stimulation in Parkinson Disease: A Retrospective Study". *Neuromodulation*. 2023 Feb 9:S1094-7159(23)00008-9. doi: 10.1016/j.neurom.2022.12.013. PMID: 36774326.
 - 11- Conti M, Stefani A, Bovenzi R, **Cerroni R**, Garasto E, Placidi F, Liguori C, Schirinzi T, Mercuri NB, Pierantozzi M. "STN-DBS Induces Acute Changes in β -Band Cortical Functional Connectivity in Patients with Parkinson's Disease". *Brain Sci*. 2022 Nov 23;12(12):1606. doi: 10.3390/brainsci12121606. PMID: 36552066.
 - 12- De Masi C, Liguori C, Spanetta M, Fernandes M, **Cerroni R**, Garasto E, Pierantozzi M, Mercuri NB, Stefani A. "Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study". *J Neural Transm (Vienna)*. 2022 Nov;129(11):1331-1338. doi: 10.1007/s00702-022-02538-w. Epub 2022 Sep 7. PMID: 36070008.
 - 13- Liguori C, Fernandes M, **Cerroni R**, Ludovisi R, Mercuri NB, Stefani A, Pierantozzi M. "Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence". *Neurol Sci*. 2022 Sep;43(9):5355-5362. doi: 10.1007/s10072-022-06111-x. Epub 2022 May 10. PMID: 35536495.
 - 14- **Cerroni R**, Pietrucci D, Teofani A, Chillemi G, Liguori C, Pierantozzi M, Unida V, Selmani S, Mercuri NB, Stefani A. "Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease". *Brain Sci*. 2022 Jun 4;12(6):739. doi: 10.3390/brainsci12060739. PMID: 35741624.

- 15- Zanela A, Schirinzi T, Mercuri NB, Stefani A, Romagnoli C, Annino G, Bonaiuto V, **Cerroni R**. Using a Video Device and a Deep Learning-Based Pose Estimator to Assess Gait Impairment in Neurodegenerative Related Disorders: A Pilot Study. *Applied Sciences*. 2022; 12(9):4642. <https://doi.org/10.3390/app12094642>
- 16- Conti M, Bovenzi R, Garasto E, Schirinzi T, Placidi F, Mercuri NB, **Cerroni R**, Pierantozzi M, Stefani A. "Brain Functional Connectivity in de novo Parkinson's Disease Patients Based on Clinical EEG". *Front Neurol*. 2022 Mar 15;13:844745. doi: 10.3389/fneur.2022.844745. PMID: 35370899.
- 17- Stefani A, Pierantozzi M, Cardarelli S, Stefani L, **Cerroni R**, Conti M, Garasto E, Mercuri NB, Marini C, Sucapane P. "Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances From Focused Ultrasound?". *Front Neurosci*. 2022 Mar 25;16:846681. doi: 10.3389/fnins.2022.846681. PMID: 35401084.
- 18- Liguori C, Stefani A, Fernandes M, **Cerroni R**, Mercuri NB, Pierantozzi M. "Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study". *J Parkinsons Dis*. 2022;12(2):537-544. doi: 10.3233/JPD-212936. PMID: 34864690.
- 19- Bovenzi R, Conti M, **Cerroni R**, Pierantozzi M, Stefani A, Pisani A, Mercuri NB, Schirinzi T. "Adult-onset sporadic chorea: real-world data from a single-centre retrospective study". *Neurol Sci*. 2022 Jan;43(1):387-392. doi: 10.1007/s10072-021-05332-w. Epub 2021 May 26. PMID: 34041635.
- 20- Fernandes M, Pierantozzi M, Stefani A, Cattaneo C, Bonizzoni EA, **Cerroni R**, Mercuri NB, Liguori C. "Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations". *Front Neurol*. 2021 Jun 29;12:678373. doi: 10.3389/fneur.2021.678373. PMID: 34267721.
- 21- Rocchi C, **Cerroni R**, Conti M, Lauretti B, Mercuri NB, Stefani A, Pierantozzi M. "Sudomotor and cardiovascular autonomic function in de novo Parkinson's disease assessed by sudoscan and cardiovascular reflexes". *J Neurol Sci*. 2021 Aug 15;427:117502. doi: 10.1016/j.jns.2021.117502. Epub 2021 May 19. PMID: 34044239.
- 22- Liguori C, De Franco V, **Cerroni R**, Spanetta M, Mercuri NB, Stefani A, Pierantozzi M, Di Pucchio A. "Sleep problems affect quality of life in Parkinson's disease along disease progression". *Sleep Med*. 2021 May;81:307-311. doi: 10.1016/j.sleep.2021.02.036. Epub 2021 Feb 25. PMID: 33756280.
- 23- Piano C, Bove F, Tufo T, Imbimbo I, Genovese D, Stefani A, Marano M, Peppe A, Brusa L, **Cerroni R**, Motolese F, Di Stasio E, Mazza M, Daniele A, Olivi A, Calabresi P, Bentivoglio AR; Lazio DBS Study Group. "Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey". *Front Neurol*. 2020 Dec 16;11:616550. doi: 10.3389/fneur.2020.616550. PMID: 33391174.
- 24- Sisto R, Viziano A, Stefani A, Moleti A, **Cerroni R**, Liguori C, Garasto E, Pierantozzi M. "Lateralization of cochlear dysfunction as a specific biomarker of Parkinson's disease". *Brain Commun*. 2020 Sep 18;2(2):fcaa144. doi: 10.1093/braincomms/fcaa144. PMID: 33376982.
- 25- **Cerroni R**, Scalise S, Stefani A. "Coronavirus Disease 2019 and Management of Advanced Therapies in Parkinson's Disease; Peculiar Needs for Deep Brain Stimulation Patients?". *Mov Disord Clin Pract*. 2020 Aug 26;7(7):875-876. doi: 10.1002/mdc3.13033. PMID: 33043092.
- 26- **Cerroni R**, Pierantozzi M, Moleti A, Stefani A, Sisto R, Mercuri NB, Liguori C, Garasto E, Viziano A. "Laterality of Auditory Dysfunction in Parkinson's Disease". *Mov Disord*. 2020 Jul;35(7):1283-1284. doi: 10.1002/mds.28131. PMID: 32691911.
- 27- Schirinzi T, Di Lazzaro G, Salimei C, **Cerroni R**, Liguori C, Scalise S, Alwardat M, Mercuri NB, Pierantozzi M, Stefani A, Pisani A. "Physical activity changes and correlate effects in patients with Parkinson's disease during COVID-19 lockdown". *Mov Disord Clin Pract*. 2020 Aug 17;7(7):797-802. doi: 10.1002/mdc3.13026. PMID: 32837960; PMCID: PMC7404747.
- 28- **Cerroni R**, Liguori C, Stefani A, Conti M, Garasto E, Pierantozzi M, Mercuri NB, Bernardini S, Fucci G, Massoud R. "Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism". *Front Aging Neurosci*. 2020 Jun 16;12:126. doi: 10.3389/fnagi.2020.00126. eCollection 2020. PMID: 32612521.
- 29- Schirinzi T, **Cerroni R**, Di Lazzaro G, Liguori C, Scalise S, Bovenzi R, Conti M, Garasto E, Mercuri NB, Pierantozzi M, Pisani A, Stefani A. "Self-reported needs of patients with Parkinson's disease

- during COVID-19 emergency in Italy". *Neurol Sci.* 2020 Jun;41(6):1373-1375. doi: 10.1007/s10072-020-04442-1. Epub 2020 May 3. PMID: 32363506.
- 30- Stefani A, **Cerroni R**, Pierantozzi M, D'Angelo V, Grandi L, Spanetta M, Galati S. "Deep Brain Stimulation in Parkinson's disease patients and routine 6-OHDA rodent models: synergies and pitfalls". *Eur J Neurosci.* 2021 Apr;53(7):2322-2343. doi: 10.1111/ejn.14950. Epub 2020 Oct 23. PMID: 32853415.
- 31- Pietrucci D, Teofani A, Unida V, **Cerroni R**, Biocca S, Stefani A, Desideri A. Can Gut Microbiota Be a Good Predictor for Parkinson's Disease? A Machine Learning Approach. *Brain Sci.* 2020 Apr 19;10(4):E242. doi: 10.3390/brainsci10040242. PMID: 32325848.
- 32- **Cerroni R**, Scalise S, Imbriani P, Liguori C, Pierantozzi M, Pisani A, Mercuri NB, Stefani A. Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. *Parkinsonism Relat Disord.* 2020 Apr;73:57-59. doi: 10.1016/j.parkreldis.2020.03.024. Epub 2020 Mar 27.
- 33- **Collaborator** in: Balestrino R, Hurtado-Gonzalez CA, Stocchi F, Radicati FG, Chaudhuri KR, Rodriguez-Blazquez C, Martinez-Martin P; PDCS European Study Group. Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). *NPJ Parkinsons Dis.* 2019 Nov 27;5:26. doi: 10.1038/s41531-019-0097-1. PMID: 31798050.
- 34- Ceravolo MG, **Cerroni R**, Farina V, Fattobene L, Leonelli L, Mercuri NB, Raggetti G. Attention Allocation to Financial Information: The Role of Color and Impulsivity Personality Trait. *Front Neurosci.* 2019 Aug 6;13:818. doi: 10.3389/fnins.2019.00818. eCollection 2019. PMID: 31447637.
- 35- Pietrucci D, **Cerroni R**, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Stefani A, Desideri A. Dysbiosis of gut microbiota in a selected population of Parkinson's patients. *Parkinsonism Relat Disord.* 2019 Aug;65:124-130. doi: 10.1016/j.parkreldis.2019.06.003. Epub 2019 Jun 3. PMID: 31174953.
- 36- **Collaborator** in: Martinez-Martin P, Radicati FG, Rodriguez Blazquez C, Wetmore J, Kovacs N, Ray Chaudhuri K, Stocchi F; PDCS European Study Group. Extensive validation study of the Parkinson's Disease Composite Scale. *Eur J Neurol.* 2019 Oct;26(10):1281-1288. doi: 10.1111/ene.13976. Epub 2019 May 31.
- 37- Olivola E, Brusa L, Rocchi C, Schillaci O, Liguori C, **Cerroni R**, Pierantozzi M, Chiaravalloti A, Stefani A, Stocchi F. Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction? *Neurol Sci.* 2018 Sep 25. doi: 10.1007/s10072-018-3569-x. PMID: 30255487.
- 38- Stefani A, **Cerroni R**, Mazzone P, Liguori C, Di Giovanni G, Pierantozzi M, Galati S. Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. *Eur J Neurosci.* 2019 Mar;49(6):805-816. doi: 10.1111/ejn.14088. Epub 2018 Aug 12 Review. PMID: 30044030.
- 39- Schirinzi T, Scalise S, Di Lazzaro G, **Cerroni R**, Chiaravalloti A, Lavorenti Figueras P, Pierantozzi M, Pisani A, Stefani A. Dopaminergic involvement in a drummer with focal dystonia: A case study. *Clin Neurol Neurosurg.* 2018 Mar;166:54-55. doi: 10.1016/j.clineuro.2018.01.023. Epub 2018 Jan 31. Erratum in: *Clin Neurol Neurosurg.* 2018 Mar 28. PMID: 29408773
- 40- Pellicano C, Assogna F, Cellupica N, Piras F, Pierantozzi M, Stefani A, **Cerroni R**, Mercuri B, Caltagirone C, Pontieri FE, Spalletta G. Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. *Parkinsonism Relat Disord.* 2017 Dec;45:50-56. doi: 10.1016/j.parkreldis.2017.10.002. Epub 2017 Oct 6. PMID: 29037499.
- 41- Stefani A, Pierantozzi M, Olivola E, Galati S, **Cerroni R**, D'Angelo V, Hainsworth AH, Saviozzi V, Fedele E, Liguori C. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. *Neurochem Int.* 2017 Jan 18. pii: S0197-0186(16)30321-7. doi: 10.1016/j.neuint.2017.01.007. PMID: 28108196.
- 42- Liguori C, Olivola E, Pierantozzi M, **Cerroni R**, Galati S, Saviozzi V, Mercuri NB, Stefani A. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. *CNS Neurol Disord Drug Targets.* 2016 Dec 5. PMID: 27934563.

- 43- Olivola E, **Cerroni R**, Conti M, Pierantozzi M, Liguori C, Stefani A. Low Serum 25(OH)D Levels in Parkinson's Disease; a Non Specific Marker of Neurodegeneration? *J Alzheimers Dis Parkinsonism* 2015, 5:3. <http://dx.doi.org/10.4172/2161-0460.1000200>.

Editorial Activities

- Invited ad hoc reviewer for *Frontiers in Neurology, Parkinsonism and Related Disorders, PLOS One* and many others.
- Member of Editorial Board (Review Editor) of *Frontiers in Neurology*

Books

Chapter Author in:

- 1- Schirinzi T, **Cerroni R**, Mercuri NB. Chapter XI – Parkinson's Disease: 11.1 Introduction and epidemiology; Chapter XV – Amyotrophic lateral sclerosis: 15.1 Epidemiology and pathogenesis in "Handbook of Neurorehabilitation and Principles of Neurology"; edited by Giunti Editore, 2021
- 2- **Cerroni R**, Schirinzi T, Mercuri NB. Chapter XI – Parkinson's Disease: 11.2 Pathology, diagnosis and clinical features; Chapter XV – Amyotrophic lateral sclerosis: 15.2 Clinical features, diagnosis and treatment in "Handbook of Neurorehabilitation and Principles of Neurology – Fondazione Santa Lucia"; edited by Giunti Editore, 2021
- 3- **Cerroni R**, Albanese M, Mercuri NB. Reward, Economic Choices, Decision Making and Dopamine. In "Neuroeconomics: Theory, Applications and Perspectives"; p. 65-82, edited by EGEA, BUP – Bocconi University Press – Milano, 2018

Working/Research groups

- Member of "Rete Deep Brain Stimulation Regione Lazio"
- Member of "Research Group for NeuroEconomics" in collaboration with University Politecnica delle Marche

Congress Activities

1. Oral Communication at LIII SIN Congress, Oct 2023, Naples, Italy. Dysbiosis of gut microbiota in Parkinson's disease as a potential biomarker of disease severity and progression. **R. Cerroni**, D. Pietrucci, M. Conti, M. Pierantozzi, N.B. Mercuri, G. Chillemi, A. Stefani.
2. Oral Communication at VII LIMPE-DISMOV Congress, Dec 2021, Bologna, Italy. Dysbiosis of gut microbiota in Parkinson's disease patients: early feature and biomarker of disease progression?. **R. Cerroni R**, Pietrucci D, Conti M, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Desideri A, Stefani A
3. Oral Communication at XLX SIN Congress, Oct 2019, Bologna, Italy. Dysbiosis of gut Microbiota in a selected population of Parkinson's Disease patients. **Cerroni R**, Pietrucci D, Conti M, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Garasto E, Desideri A, Stefani A.
4. Poster at XLX SIN Congress, Oct 2019, Bologna, Italy. An insight into cochlear impairment in Parkinson's Disease; a distortion product otoacoustic emission study. **Cerroni R**, Viziano A, Garasto E, Sisto R, Mercuri NB, Moleti A, Stefani A, Pierantozzi M.

5. Poster at V LIMPE/DISMOV Congress, May 2019, Catania, Italy. Parkinson's disease and Microbiota in a selected population from center Italy. **Cerroni R**, Conti M, Pierantozzi M, Mercuri NB, Stefani A, Pietrucci D, Unida V, Biocca S, Desideri A.
 6. Oral Communication at XLIX SIN Congress, Oct 2018, Roma, Italia. Parkinson's disease and Microbiota: ongoing analysis on a large cohort at the university of Rome Tor Vergata. **Cerroni R**, Stefani A, Pierantozzi M, Mercuri NB, Pietrucci D, Unida V, Biocca S, Desideri A.
 7. Poster at IV LIMPE/DISMOV Congress, May 2018, Roma, Italy. Parkinson's disease and Microbiota: the experience at the University of Rome "Tor Vergata". **Cerroni R**, Conti M, Pierantozzi M, Mercuri NB, Stefani A, Pietrucci D, Unida V, Biocca S, Desideri A.
 8. Poster at II LIMPE/DISMOV Congress, May 2016, Bari, Italy. Low cerebrospinal fluid 3,4-Dihydroxyphenylacetic Acid and 3,4- Dihydroxyphenylglycol levels are Biomarkers of Parkinsonian Disorders. Olivola E, Stefani A, Pierantozzi M, **Cerroni R**, Holmes C, Sharabi Y, Goldstein DS
 9. Poster at I LIMPE/DISMOV Congress, September 2015, Torino, Italy. Continuous dopaminergic stimulation with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report. **Cerroni R**, Imbriani P., Schirizzi T., Olivola E., Stefani A., Pisani A.
-

Clinical trials

1. A double-blind, placebo-controlled, randomized, 18-month Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson's Disease. **PD0053**. Sponsor: UCB. Role: Sub-Investigator. (ongoing)
2. "Efficacia e sicurezza di Opicapone in pazienti con malattia di Parkinson e fluttuazioni motorie: uno studio osservazionale retrospettivo/prospettico". **OPENPARK**. Sponsor: BIAL. Role: Sub-Investigator. (ongoing)
3. Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients. **SCOL Study. TP-007**. Sponsor: Synagile. Role: Sub-Investigator (ongoing).
4. A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BOUNDless). **ND0612-317**. Sponsored by: Neuroderm. Role: DeputyPI (ongoing).
5. "A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure" - **TD-9855**. sponsored by Theravance. Role: Sub-investigator/Rater (2020-2021) (PI: Camilla Rocchi).
6. "A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients with Motor Fluctuations" - IMPAX **IPX203-B16-02**, sponsored by: Impax Laboratories, LLC . Role: Sub-investigator (2019-2021) (PI: Prof A. Stefani).
7. An Open-label, phase III, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Advanced Parkinson's Disease - **DYSCOVER (DYSkinesia Comparative interventional trial on Duodopa VERSus oral medication) - M15-535**, sponsored by Abbvie. Role: Sub-investigator/Rater (2017-2019) (PI: Prof A. Stefani).
8. Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in Parkinson's Disease (PD). **CASPAR study**, sponsored by Linical. Role: Sub-investigator/Rater (2018-2019) (PI: Prof. F. Placidi)

9. Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson's Disease experiencing motor fluctuations, Phase IIa. **EXN-32CD-002**, sponsored by Dr Reddy's. Role: Sub-investigator/Rater (2018) (PI: Prof A. Stefani)
10. A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson's Disease Complicated by Motor Fluctuations ("OFF Episodes"). **CTH-201**, sponsored by Sunovion Pharmaceuticals. Role: Sub-investigator/Rater (2018) (PI: Prof A. Stefani)
11. Ruolo della Citicolina nella Terapia di supporto della Malattia di Parkinson - **CITIPARK**, sponsored by PIAM Farmaceutici SpA. Role: Sub-investigator/Rater (ongoing) (PI: Prof A. Stefani).
12. A multi-country, OBSERVational, cross-sectional study to characterize advanced Parkinson's Disease patients in Movement disorder Centers (**OBSERVE-PD**), sponsored by AbbVie. Role: Sub-investigator/Rater (2015) (PI: Prof. A. Stefani).

Autorizzo il trattamento dei dati in base al regolamento UE 20016/679



Roma, 17/11/2023